All In Biotech

Drug Trial Radar · NCT01993186

Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome

Last checked: Nov 20, 2026Latest source record: Jun 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Feb 28, 2014

Primary completion

Sep 20, 2017

Study completion Sep 20, 2017

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Nov 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are to evaluate the efficacy of UX007 compared to placebo as measured by the reduction from randomization to Week 8 in frequency of seizures and to evaluate the safety of UX007 via adverse event (AE) rates, laboratory values, and electrocardiogram (ECG).

Conditions

  • Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Interventions

  • UX007Drug

    oral liquid

  • PlaceboDrug

    oral liquid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Reduction From Baseline to Week 8 in Frequency of Total Seizures (Normalized to a 4-Week Rate)Time frame: Baseline, Week 8
  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Discontinuations Due to TEAEs During the Placebo-Controlled PeriodTime frame: Weeks 0 to 8
  3. Number of Participants With TEAEs, Serious TEAEs and Discontinuations Due to TEAEs During the Extension PeriodTime frame: Weeks 9 to 52 plus 30 days

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado - University of Colorado, Denver, School of Medicine

    Aurora, Colorado

  • Miami Children's Research Institute

    Miami, Florida

  • Neurology & Epilepsy Research Center

    Orlando, Florida

  • Columbia University - Department of Neurology

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Cook Children's Hospital

    Fort Worth, Texas

  • University of Texas Neurometabolic Clinic

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

  • Melbourne Brain Centre

    Heidelberg, Victoria, Australia

  • Service de Neurologie Pédiatrique et des Maladies Métaboliques - INSERM U1141 Hôpital Robert Debré - APHP

    Paris, Cedex 19, France

  • Sheba University Medical Center

    Tel Aviv, Israel

  • Unita' Operativa Neurologia Pediatrica e Malattie Muscolari Istituto "Giannina Gaslini"

    Genova, Italy

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Newcastle University

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.